Lean Six Sigma - Its application to drug discovery By Clare Hammond and Charles J O'Donnell In an increasingly competitive world, the race between pharmas to get high quality candidate drugs to market is on. Contributing to this success is the discovery phase of lead optimisation. The application of Lean… Read More
Human ES Cell Derived Functional Cells as Tools in Drug Discovery By Dr Petter Bjorquist, Dr Peter Sartipy, Dr Raimund Strehl and Dr Johan Hyllner The drug discovery process is extremely-time consuming and expensive. Consequently, novel approaches for these processes and for reducing late-stage attrition are of great value for… Read More
Perspectives for ADMET Integration in the Discovery Process By Dr Constance Hofer ADMET (ADME/Tox), is a relatively new symbiotic acronym for the investigation of basic compound behaviour in terms of absorption, distribution, metabolism and excretion, combined with assessments of toxicity. The emergence of ADMET instead of ADME reflects the growing… Read More
Novartis Vaccines - Leading through innovation and technology By Dr Joerg Reinhardt Every year, vaccines save millions of lives by preventing major human diseases, protecting individuals and those close to them, and offering widespread public defence against disease. In 2006, Novartis joined the vaccines market when it acquired Chiron, creating… Read More
How Non-invasive Visible Light Imaging Can Change Drug Discovery Dr Peter Lassota and Dr Anjani Shah In the past decade, non-invasive visible light imaging gained acceptance not only as a valuable research tool, but also as a means of evaluating new compounds for efficacy and pharmacodynamic properties in drug discovery. Read More
Industry Strategies on Theranostics: Need for structural alignment Dr Rutger O. van Merkerk and Dr Wouter P.C. Boon Theranostics is said to change the way patients will manage their disease. Such a change assumes that diagnostics and therapeutics become increasingly linked based on genetic information. Companies that adhere to this… Read More
The Deming Approach to Quality In Pharmaceutical Research By John H. Van Drie We explore the relevance to pharmaceutical research of the ideas of W. Edwards Deming, the statistician whose ideas on quality transformed the manufacturing sector of post-war Japan. To enhance productivity in pharmaceutical research, we have tended to… Read More
Reshaping the Landscape of Cancer Drug Discovery and Development By Dr Paolo Paoletti The landscape of cancer drug discovery and development is shifting, adjusting and reshaping itself in response to the huge rush of scientific knowledge which has come to the fore over the past few decades. In collaboration with… Read More
Designing animal models for evaluation of therapeutic and vaccine candidates for emerging and biodefence-related pathogens By Dr Colleen Jonsson and Dr Peter Silvera While a number of promising drug therapies and vaccines have been identified for safeguarding bioterrorism organisms and diseases, further development requires well characterised animal models for testing… Read More
The evolving world of drug discovery data integration in the pharmaceutical industry Dr David Sedlock The world of drug discovery has been impacted significantly by an ever evolving use of computer systems during the past 25 years with the greatest change occurring during the past 10 years or so as… Read More
By Dr Jean-Luc Vanderheyden As the experience and advances in Positron Emission Tomography (PET) imaging grows, so does the belief that this technology can have a key role to play in ushering in an era of personalised medicine while also offering an enormous contribution in reducing the attrition rates in… Read More
By Anthony Rosenberg Partnering and licensing have become paramount in a pharmaceutical industry that is under inordinate pressure to fill pipelines and increase the number of approved new molecular entities. This article discusses how Novartis has gone about addressing this issue. There is a great deal of focus on discovering… Read More
India - Global pharmaceutical R&D powerhouse or contract research workshop? By Dr Matthew Howard In response to the ever-increasing costs of drug discovery and development, pharmaceutical industry leaders must constantly seek to increase productivity while simultaneously reducing costs and maintaining quality. Globalisation of drug discovery may provide such an opportunity,… Read More
The Role of Repositioning in Drug Discovery and Development By Dr Louis A. Tartaglia and Dr Lee E. Babiss The large number of drug candidate failures in recent years has been enormously costly for the pharmaceutical industry, but has also created the tremendous opportunity of repositioning these molecules into new… Read More
Innovative Partnerships in Neglected Disease Research - The Novartis Institute for Tropical Diseases By Prof Paul Herrling While the recent biomedical revolution has given rise to significant advances in medical treatment, many neglected diseases that are endemic in underdeveloped parts of the world remain unaddressed. Public-private partnerships like the Novartis… Read More
Zebrafish: a versatile in vivo model for drug safety assessment Dr Wendy Alderton and Dr St phane Berghmans Safety pharmacology has become an integral part of non-clinical safety assessment for new chemical entities in the past two decades (1). The relative novelty of this discipline has granted it the flexibility… Read More